Autoantibodies against N-homocysteinylated proteins in humans: Implications for atherosclerosis

Stroke

Volumn 35, Issue 6, 2004, Pages 1299-1304

  Undas, Anetta ^c   Perła, Joanna ^b,c   Łacinski, Mariusz ^a   Trzeciak, Wiesław ^a   Kaźmierski, Radosław ^a   Jakubowski, Hieronim ^b,c  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Atherosclerosis; Dose response relationship, immunologic; Homocysteine; Immune system; Immune tolerance; Proteins; Stroke

Indexed keywords

AUTOANTIBODY; CYSTEINE; EPITOPE; HOMOCYSTEINE THIOLACTONE; METHIONINE;

ADULT; AMINO ACID BLOOD LEVEL; ANTIBODY BLOOD LEVEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; HYPOTHESIS; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; QUANTITATIVE ANALYSIS;

AGED; ARTERIOSCLEROSIS; AUTOANTIBODIES; BLOOD PROTEINS; CEREBROVASCULAR ACCIDENT; EPITOPES; FEMALE; HOMOCYSTEINE; HUMANS; IMMUNOGLOBULIN G; LYSINE; MALE; MIDDLE AGED;

EID: 2542618547     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.0000128412.59768.6e     Document Type: Article

References (20)

1. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002;288: 2015-2022.
2. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291: 565-575.
3. Anderson JL, Muhlestein JB, Horne BD, Carlquist JF, Bair TL, Madsen TE, Pearson RR. Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with angiographically defined coronary artery disease. Circulation. 2000;102: 1227-1232.
4. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D'Agostino RB, Wilson PW, Wolf PA. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346:476-483.
5. Mattson MP, Shea TB. Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci. 2003;26: 137-146.
6. Jakubowski H, Goldman E. Synthesis of homocysteine thiolactone by methionyl-tRNA synthetase in cultured mammalian cells. FEBS Lett. 1993;317:593-598.
7. Jakubowski H. Metabolism of homocysteine thiolactone in human cell cultures: possible mechanism for pathological consequences of elevated homocysteine levels. J Biol Chem. 1997;272:1935-1942.
8. Jakubowski H, Zhang L, Bardeguez A, Aviv A. Homocysteine thiolactone and protein homocysteinylation in human endothelial cells: implications for atherosclerosis. Circ Res. 2000;87:45-51.
9. Jakubowski H. The determination of homocysteine-thiolactone in biological samples. Anal Biochem. 2002;308:112-119.
10. Jakubowski H. Translational accuracy of aminoacyl-tRNA synthetases: implications for atherosclerosis. J Nutr. 2001;131:2983-2987.
11. Jakubowski H. Homocysteine-thiolactone and S-nitroso-homocysteine mediate incorporation of homocysteine into protein in humans. Clin Chem Lab Med. 2003;41:1462-1466.
12. Jakubowski H. Biochemical basis of homocysteine toxicity in humans. Mol Cell Life Sci. 2004;61:470-487.
13. Jakubowski H. Homocysteine is a protein amino acid in humans: implications for homocysteine-linked disease. J Biol Chem. 2002;277: 30425-30428.
14. Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J. 1999;13:2277-2283.
15. Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A, Witztum JL. Innate and acquired immunity in atherosclerosis. Nat Med. 2002;8:1218-1226.
16. Virella G, Thorpe SR, Alderson NL, Stephan EM, Atchley D, Wagner F, Lopes-Virella MF; DCCT/EDIC Research Group. Autoimmune response to advanced glycosylation end-products of human LDL. J Lipid Res. 2003;44:487-493.
17. Accinni R, Bartesaghi S, De Leo G, Cursano CF, Achilli G, Loaldi A, Cellerino C, Parodi O. Screening of homocysteine from newborn blood spots by high performance liquid chromatography with coulometric detection. J Chromatogr A. 2000;896:183-189.
18. Ferguson E, Parthasarathy S, Joseph J, Kalyanaraman B. Generation and initial characterization of a novel polyclonal antibody directed against homocysteine thiolactone-modified low-density lipoprotein. J Lipid Res. 1998;39:925-933.
19. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
20. Widner B, Leblhuber F, Frick B, Laich A, Artner-Dworzak E, Fuchs D. Moderate hyperhomocysteinaemia and immune activation in Parkinson's disease. J Neural Transm. 2002;109:1445-1452.